Search Results

In its legal complaint, filed in the District Court for New Jersey, Regeneron alleges that Sandoz failed to provide it with relevant information required under the Biologics Price Competition and Innovation Act.

Prescriptions for Sandoz’s Hyrimoz, a biosimilar version of AbbVie’s Humira, have shot up after CVS Caremark took the blockbuster arthritis treatment off its major national commercial formularies on April 1.

Sandoz, the global leader in generic and biosimilar medicines, announced net sales for the first quarter 2024.

Jacobio Pharma, a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib in combination with a SHP2 inhibitor in frontline non-small cell lung cancer patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology Annual Meeting as form of oral presentation.

Jacobio Pharma announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.

Sandoz, the global leader in generic and biosimilar medicines, announced that the European Commission has granted marketing authorization for Wyost®1 and Jubbonti®2, the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe.

The Board of Directors of Sandoz announced that it proposes Mathai Mammen, M.D., Ph.D., and Michael Rechsteiner for election to its Board of Directors at the company’s Annual General Meeting on April 30, 2024.